Dapagliflozin as Add ‐on Therapy in Asian Patients with Type 2 Diabetes Inadequately Controlled on Insulin ± Oral Antihyperglycemic Drugs: A Randomized Controlled Trial
ConclusionsDapagliflozin as add‐on to insulin ± OADs significantly improved glycemic control and reduced body weight and blood pressure in Asian patients. Dapagliflozin was well tolerated, with a similar frequency of hypoglycemia in both groups. These results support the use of dapagliflozin as add‐on to insulin ± OADs in this population.This study was funded by AstraZeneca.
HighlightsDapagliflozin 10 mg as add‐on to insulin ± oral antihyperglycemic drugs significantly improved glycemic control and reduced body weight and blood pressure, without increased risk of hypoglycemia, compared with placebo in this 24‐week, phase 3, double‐blind, placebo‐controlled study in Asian patients with type 2 diabetes mellitus inadequately controlled on insulin ± oral antihyperglycemic drugs.
Source: Journal of Diabetes - Category: Endocrinology Authors: Wenying Yang, Jianhua Ma, Yiming Li, Yanbing Li, Zhiguang Zhou, Jae Hyeon Kim, June Zhao, Agata Ptaszynska Tags: Original Article Source Type: research
More News: AstraZeneca | Dapagliflozin | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Eyes | Forxiga | Insulin | Study